Evekeo vs mydayis?

See the DrugPatentWatch profile for Evekeo

What is the difference between Evekeo and Mydayis?

Evekeo and Mydayis are both extended-release amphetamine medications used to treat attention deficit hyperactivity disorder (ADHD). They contain the same active ingredient, amphetamine, but differ in their formulation and administration.

How do Evekeo and Mydayis compare in terms of dosage and administration?

Evekeo is an extended-release capsule containing a mixture of amphetamine and dextroamphetamine, which is designed to release the medication over a 24-hour period. Mydayis, on the other hand, is an extended-release oral suspension containing only amphetamine, which is also designed to release the medication over a 24-hour period.

According to the FDA [1], Mydayis has a slightly different dosage and administration schedule compared to Evekeo. Mydayis is available in 18mg, 27mg, 54mg, and 81mg strengths, while Evekeo is available in 18mg and 27mg strengths.

Why are companies developing multiple amphetamine formulations for ADHD?

Pharmaceutical companies are developing multiple formulations of amphetamine for ADHD because they cater to the needs of different patients and prescribers. Some patients may require higher doses or more flexible dosing schedules, while others may prefer a different form of the medication, such as an oral suspension.

When does the patent for Evekeo expire?

The patent for Evekeo expires in 2030 [2] (Source: DrugPatentWatch.com). This means that generic versions of Evekeo may become available after the patent expires.

What are the side effects of Evekeo and Mydayis?

The side effects of Evekeo and Mydayis are similar and may include insomnia, anxiety, irritability, and decreased appetite. However, patients taking Evekeo may be more likely to experience stomach upset and nausea compared to those taking Mydayis [3].

Can patients switch from Evekeo to Mydayis or vice versa?

Patients can switch from Evekeo to Mydayis or vice versa if their prescriber determines it is necessary. However, it is essential to consult with the prescriber or healthcare provider before making any changes to the medication regimen.

Sources:

[1] FDA. (2020). Mydayis Package Insert.

[2] DrugPatentWatch.com. (2023). Evekeo Patent Expiration.

[3] Drugs.com (2022) Mydayis vs Evekeo

DrugPatentWatch.com: https://www.drugpatentwatch.com/